Sotera Health Company Form 8-K Summary
Business context and reporting period
Sotera Health Company filed this Form 8-K on June 26, 2023, under Items 5.02, 7.01, and 9.01. The filing reports a change in senior management and furnishes a related press release. It does not provide quarterly or annual operating results.
Key financial and operating metrics
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics are reported.
- Jonathan M. Lyons was appointed Senior Vice President and Chief Financial Officer, effective June 26, 2023.
- Mr. Lyons succeeds Michael F. Biehl, who had been serving as Interim CFO.
- Mr. Lyons will also serve as the Company’s principal accounting officer.
Material changes versus the prior comparable period
The material change is the appointment of a permanent CFO following the interim CFO period. The filing does not present comparable-period financial information or quantify any related financial impact.
Compensation, outlook, risks, and unusual items
- Annual base salary: $475,000.
- Target annual bonus: 70% of annual base salary, prorated for the 2023 start date.
- Annual long-term incentive target grant-date fair value: $1.2 million, prorated for 2023. The disclosed 2023 award includes RSUs and stock options, each with a target grant-date fair value of $300,000.
- Sign-on cash payment: $200,000, subject to pro-rated repayment under specified termination circumstances before June 26, 2025.
- Sign-on equity award: RSUs with a grant-date fair value of $1.0 million, vesting in substantially equal annual installments over three years.
- If the Company terminates Mr. Lyons without cause, he may receive 12 months of continued base salary, subject to specified conditions including execution of a general release.
- The filing states there was no undisclosed appointment arrangement, family relationship with another officer or director, or reportable related-party transaction involving Mr. Lyons.
- Management guidance, business outlook, contingencies, litigation developments, and risk-factor updates are not provided in the filing text.
Investor verification points
- Verify the final grant dates, vesting terms, and accounting treatment of the sign-on and annual equity awards.
- Assess the transition from the Interim CFO and any subsequent changes in finance leadership or reporting controls.
- Review later filings for disclosure of the CFO’s actual compensation, termination provisions, or material impact on expenses.
- Read Exhibit 99.1, the June 26, 2023 press release, for any additional management commentary.